However, because omalizumab clearance at clinical doses is dominated by the reticular endothelial system (RES), it is unlikely to be altered by renal impairment. While no particular dose adjustment is recommended, Xolair should be administered with caution in patients with renal impairment. It is important to discuss the use of Xolair with a healthcare professional if you have kidney disease to determine the potential risks and benefits.
